尤里卡启动了用于肝癌的新型T细胞疗法的1/2阶段试验

StephenW

Eureka launches phase 1/2 trial of novel T-cell therapy for liver cancer
August 7, 2019

Eureka Therapeutics has initiated a phase 1/2 clinical trial of its ET140202 Artemis T-cell therapy for the treatment of liver cancer, according to a press release.

The company will evaluate ET140202 in combination with its Artemis antibody T-cell receptor platform that was engineered with human TCR-mimic antibody to target an alpha fetoprotein-peptide/HLA-A2 complex on hepatocellular cancer cells.

“Traditional immunotherapy such as checkpoint inhibitors releases the breaks on the immune system, which allows it to sometimes attack the tumor but can also lead to attacks on other parts of the human body,” Daneng Li, MD, principal investigator of the ongoing study and a medical oncologist at City of Hope in California, said in the release. “This approach engineers immune cells to directly attack a protein that is expressed on liver cancer. We are trying to individualize treatment for patients with advanced liver cancer.”

Previous studies have demonstrated a favorable safety profile with no observed cytokine release syndrome or drug-related neurotoxicity in treated patients.

Patients selected for the phase 1/2 trial have metastatic or locally advanced inoperable liver cancer who are incapable of tolerating at least one line of treatment for their disease.

“We are pleased to work with City of Hope on bringing ET140202 therapy to patients with advanced HCC,” Cheng Liu, MD, PhD, founder and CEO of Eureka Therapeutics, said. “Our approach has been to use our Artemis T-cell platform with higher target specificity to address the safety and other challenges in the treatment of solid tumors. HCC is a devastating disease, and we are delighted that City of Hope is using their broad expertise to potentially accelerate our efforts and provide additional opportunities to combat this and other diseases.”

Reference: www.eurekatherapeutics.com

StephenW

尤里卡启动了用于肝癌的新型T细胞疗法的1/2阶段试验
2019年8月7日

根据一份新闻稿，Eureka Therapeutics已开始其ET140202 Artemis T细胞疗法治疗肝癌的1/2期临床试验。

该公司将评估ET140202与其Artemis抗体T细胞受体平台的组合，该平台使用人TCR模拟抗体工程化，以靶向肝细胞癌细胞上的甲胎蛋白肽/ HLA-A2复合物。

“传统的免疫疗法，如检查点抑制剂会释放免疫系统的断裂，使其有时会攻击肿瘤，但也会导致对人体其他部位的攻击，”正在进行的研究的主要研究者Daneng Li医学博士和加利福尼亚州希望市的一名肿瘤内科医生在发布会上说。 “这种方法可以使免疫细胞直接攻击在肝癌上表达的蛋白质。我们正在努力为晚期肝癌患者提供个性化治疗。“

先前的研究已经证明了有利的安全性，在治疗的患者中没有观察到细胞因子释放综合征或药物相关的神经毒性。

选择用于1/2期试验的患者具有转移性或局部晚期不能手术的肝癌，其不能耐受至少一种治疗其疾病的治疗方案。

“我们很高兴与希望之城合作，为患有晚期HCC的患者提供ET140202治疗，”Eureka Therapeutics创始人兼首席执行官Cheng Liu博士说。 “我们的方法是使用具有更高靶标特异性的Artemis T细胞平台来解决实体瘤治疗中的安全性和其他挑战。 HCC是一种毁灭性的疾病，我们很高兴希望之城利用其广泛的专业知识来加速我们的努力并提供额外的机会来对抗这种疾病和其他疾病。“

参考：www.eurekatherapeutics.com